Scholar Rock Holding Corp TOPAZ Phase 2 Clinical Trial Data Transcript
Good day, and welcome to the Scholar Rock Conference Call. (Operator Instructions).
As a reminder, this call is being recorded. I would now like to turn the call over to [Rashmi Nofsinger], Vice President of Investor Relations and Corporate Affairs. You may begin.
Good morning, and thank you for joining us on today's call to review the 24-month extension period results from our TOPAZ Phase II clinical trial of patients with Type 2 and Type 3 spinal muscular atrophy, or SMA. The webcast slides for this call can be accessed on the Events and Presentations section of the Investor Relations page on the Scholar Rock website.
I wanted to note that we'll be making various statements about Scholar Rock's future expectations, plans and prospects that constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by any forward-looking statements as a result of various
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |